Formulation Development
Can-Fite Has Raised $175 Million for the Development of Namodenoson & Piclidenoson
Can-Fite BioPharma Ltd. recently announced it has raised $175 million in funding to date. These funds have enabled the advancement of its lead drug candidates,…
Immutep’s Efti in Combination With KEYTRUDA Drives Strong Overall Survival in Head & Neck Cancer With CPS <1
Immutep Limited recently announced an excellent median Overall Survival (OS) of 17.6 months has been achieved in Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb…
Moleculin Bolsters Annamycin Intellectual Property Portfolio With Granting of Two New U.S. Patents
Moleculin Biotech, Inc. recently announced the US Patent and Trademark Office (USPTO) has granted two additional US patents with claims covering Annamycin. US patent number…
Cell & Gene Therapy Market Set to Grow at 31.3% CAGR Through 2030
The global dermatological cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate (CAGR) of 31.3%, with sales…
Roquette Completes the Acquisition of IFF Pharma Solutions
Roquette recently announced the successful completion of its acquisition of IFF Pharma Solutions. This strategic milestone marks a significant step forward in its ambition to…
Bespak Achieves Sustainability Milestone With First Life Cycle Assessment for Pressurized Metered Dose Inhaler Valve
Bespak, a specialist inhalation contract development and manufacturing organization (CDMO), recently announced it has completed its first life cycle assessment (LCA) for its market-leading BK357…
Crown Bioscience & NEXT Oncology Cement Partnership Extension
Crown Bioscience recently announced the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. This strategic…
Actinogen Provides Pivotal Alzheimer’s Trial Enrolment Update & Other Business News
Actinogen Medical Limited recently announced its Alzheimer’s disease phase 2b/3 trial has now enrolled 60 participants and expects to reach 100 by the end of…
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
Vaxart, Inc. recently announced it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.…
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
Silo Pharma, Inc. recently announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26’s potential as…
SGS Designated as a Notified Body Under EU IVDR
SGS, the world’s leading testing, inspection and certification company, is delighted to announce the designation of SGS Belgium NV as a Notified Body (NB) under…
PCI Pharma Services to Acquire US-Based Aseptic Fill-Finish CDMO Ajinomoto Althea
PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co.,…
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients With Cyclin E1+ PROC
Zentalis Pharmaceuticals, Inc. recently announced the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in…
Purple Biotech Reports Positive NT219 Data for Colorectal & Head & Neck Cancers
Purple Biotech Ltd. recently announced two posters reporting new NT219 data presented at the American Association for Cancer Research (AACR 2025) Annual Meeting on Sunday…
Artelo Biosciences Announces New Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
Artelo Biosciences, Inc. recently announced new research published in the peer-reviewed Journal of Investigative Dermatology describing the positive effects of ART26.12 in both in vitro and in vivo…
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA From Pretargeted RIT Platform
Y-mAbs Therapeutics, Inc. recently announced the presentation of preclinical and translational pharmacokinetics (PK) data of CD38-SADA in a poster at the 2025 American Association of…
Polyrizon Reports Successful Safety Study of a Formulation of Allergy Blocker in Human Nasal Tissue Model
Polyrizon Ltd. recently announced the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product’s development…
Avidicure Launches With $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
Avidicure recently announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM,…
BriaCell Confirms 100% Resolution of Lung Metastasis With Bria-OTS
BriaCell Therapeutics Corp. confirms the sustained complete resolution of the lung metastasis, first reported in February 2025, two months after initial treatment in the ongoing…
Inmagene Reports Topline Results From Phase 2a Study of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life in Patients With Alopecia Areata
Inmagene Biopharmaceuticals recently reports topline results from the Phase 2a trial of IMG-007 in patients with severe alopecia areata (AA). “AA is an I&I disease…
